NICE Rejects Use of Cancer Drug Tarceva
14th Nov 2006, 13:38 GMT
Tarceva, a lung cancer drug manufactured by Roche, may not be approved in the UK following a negative recommendation by the National Institute for Health and Clinical Excellence.
NICE Rejects Use of Cancer Drug Tarceva related news:
- NICE rejects use of cancer drug Tarceva — Pharmaceutical Business Review Latest News
- NICE disapproves the use of cancer drug Tarceva — The Earth Times Online Newspaper
- NICE consults on advice on two treatments for NSCLC — OnMedica Latest News
- NICE refuse to fund life-prolonging cancer drug available in Scotland — the Mail online | Health
- NICE refuses to fund life-prolonging cancer drug available in Scotland — the Mail online | Health
- Watchdog rules against new treatment for lung cancer — Guardian Unlimited UK Latest
- NICE refuses to fund £20,000 cancer drug available in Scotland — the Mail online | Home
- Targeted cancer drugs may work by disrupting balance of cellular signals — EurekAlert! - Cancer
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
- Dendreon completes FDA filing for prostate-cancer drug — The Seattle Times: Horse racing
Latest news from RedOrbit News - Health:
- Pet Shop Boys Fans Know Better _ Why Bother Sharing?
- Corcept Tests Psych. Major Depression Rx
- On Its 30th Anniversary, Smokeout Provides Even More Help Quitting Smoking
- Health Plans and Disease Management Companies Are Seeking To Reduce the Use of the ER for Non-Urgent Care - Urgent Emergency Room Usage October 18, 2006 Audio Conference on CD-ROM
- Invitation Conference Call Analyst Meeting
- As Benefit Costs Rise, Employee Retirement Savings Decline
- Aetna to Help Members Quit Tobacco With New Tobacco Cessation Program
- Lilly: Arxxant Cuts Sight Loss in Diabetes
- SW Doctors PA Launch Affordable Primary Care (APC) Services
- Health Savings Technology Appoints New Management Team to Spearhead Growth in Customer-Directed Healthcare Industry